Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).

Page, David B.; Kim, Isaac K; Sanchez, Katherine; Moxon, Nicole; Mellinger, Staci L.; Conlin, Alison; Acheson, Anupama Kurup; Perlewitz, Kelly S.; Lewis, Stacy; Kemmer, Kathleen; Mitri, Zahi; Basho, Reva; Riffle, Emily; Ahn, Jenny; Pucilowska, Joanna; Martel, Maritza; Urba, Walter J.; McArthur, Heather L.

doi:10.1200/jco.2018.36.15_suppl.1033

Cited by 12 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Filipa Lynce 1,2,3,18 , Candace Mainor 4,18 , Renee N. Donahue 5,18 , Xue Geng 6 , Greg Jones 7 , Ilana Schlam 8,9 , Hongkun Wang 6 , Nicole J. Toney 5 , Caroline Jochems 5 , Jeffrey Schlom 5 , Jay Zeck 4 , Christopher Gallagher 8 , Rita Nanda 10 , Deena Graham 11 , Erica M. Stringer-Reasor 12 , Neelima Denduluri 13 , Julie Collins 4,17 , Ami Chitalia 8 , Shruti Tiwari 8 , Raquel Nunes 14,17 , Rebecca Kaltman 15 , Katia Khoury 12 , Margaret Gatti-Mays 16 , Paolo Tarantino 1,3 , Sara M. Tolaney 1,2,3 , Sandra M. Swain 6 , Paula Pohlmann 4 , Heather A. Parsons 1,2,3,19 & Claudine Isaacs 6,19 1 Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2 Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.…”

Section: Reporting Summarymentioning

confidence: 99%

“…Although KEYNOTE-522 did not allow the use of adjuvant capecitabine along with pembrolizumab, this combination is often utilized in clinical practice given the high risk of recurrence, the benefit observed with each drug alone, and the potential synergy when given together 18 , 19 . However, it is unclear if there is a benefit of PD-1/PD-L1 blockade in the adjuvant setting after preoperative chemotherapy without immunotherapy in patients without evidence of residual macroscopic tumor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Lynce,

Mainor,

Donahue

et al. 2024

Nat Commun

View full text Add to dashboard Cite

Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints included the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) is associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.

show abstract

Section: Reporting Summarymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Lynce,

Mainor,

Donahue

et al. 2024

Nat Commun

View full text Add to dashboard Cite

show abstract

“…Another study investigating pembrolizumab + eribulin in 106 patients with mTNBC and had an ORR of 26.4% (95% CI: 18.3-35.9%) with response rates similar regardless of PD-L1 status [12]. Finally, a small study (n = 12) evaluating pembrolizumab with capecitabine in mTNBC irrespective of PD-L1 expression found the ORR to be 42% [13].…”

Section: Discussionmentioning

confidence: 99%

Physician Treatment of Metastatic Triple-Negative Breast Cancer in the Immuno-Oncology Era: a Discrete Choice Experiment

et al. 2020

View full text Add to dashboard Cite

Aim: Guidelines list atezolizumab with nab-paclitaxel (ANP) as the preferred first-line (1L) therapy for metastatic triple-negative breast cancer (mTNBC) with PD-L1 expression ≥1%, but which clinical attributes impact ANP prescribing? Materials & methods: Medical oncologists participated in a discrete choice experiment (DCE) with four hypothetical mTNBC clinical scenarios to assess influences of: PD-L1 expression, menopausal status, prior adjuvant therapy and bulky liver metastases. Results: A total of 47% chose ANP in 1L irrespective of menopausal status, prior adjuvant therapy or tumor bulk. PD-L1 expression was the only attribute with a significant impact on ANP preference, with 69% choosing ANP for those with ≥1% expression versus only 26% for those with <1% (p < 0.00001). Conclusion: ANP choice for 1L mTNBC deviated from guidelines.

show abstract

“…However, the expression level of PD-L1 has a big difference in the prediction of the efficacy of ICI drugs in breast cancer. In clinical trials of ICI drugs for TNBC, the positive rate of PD-L1 expression status in tumor cells or immune cells ranged from 19.4% to 68%, and the overall response rate to ICI drugs was 5% to 42% (62,(101)(102)(103)(104)(105)(106). And it was found that patients with negative PD-L1 expression may also respond to ICI drugs (100).…”

Section: Pd-l1 Expressionmentioning

confidence: 99%

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy

Zhang

Kong

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Tumor immune escape refers to the phenomenon in which tumor cells escape the recognition and attack of the body’s immune system through various mechanisms so that they can survive and proliferate in vivo. The imbalance of immune checkpoint protein expression is the primary mechanism for breast cancer to achieve immune escape. Cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD-1)/programmed cell death protein-ligand 1 (PD-L1) are critical immune checkpoints for breast cancer. Immune checkpoint inhibitors block the checkpoint and relieve its inhibition effect on immune cells, reactivate T-cells and destroy cancer cells and restore the body’s ability to resist tumors. At present, immunological checkpoint inhibitors have made significant progress in breast cancer immunotherapy, and it is expected to become a new treatment for breast cancer.

show abstract

Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).

Cited by 12 publications

References 0 publications

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Physician Treatment of Metastatic Triple-Negative Breast Cancer in the Immuno-Oncology Era: a Discrete Choice Experiment

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy

Contact Info

Product

Resources

About